Lee, BY and Bacon, KM and Connor, DL and Willig, AM and Bailey, RR
(2010)
The potential economic value of a Trypanosoma cruzi (chagas disease) vaccine in Latin America.
PLoS Neglected Tropical Diseases, 4 (12).
1 - 8.
Abstract
Background:Chagas disease, caused by the parasite Trypanosoma cruzi (T. cruzi), is the leading etiology of non-ischemic heart disease worldwide, with Latin America bearing the majority of the burden. This substantial burden and the limitations of current interventions have motivated efforts to develop a vaccine against T. cruzi. Methodology/Principal Findings: We constructed a decision analytic Markov computer simulation model to assess the potential economic value of a T. cruzi vaccine in Latin America from the societal perspective. Each simulation run calculated the incremental cost-effectiveness ratio (ICER), or the cost per disability-adjusted life year (DALY) avoided, of vaccination. Sensitivity analyses evaluated the impact of varying key model parameters such as vaccine cost (range: $0.50-$200), vaccine efficacy (range: 25%-75%), the cost of acutephase drug treatment (range: $10-$150 to account for variations in acutephase treatment regimens), and risk of infection (range: 1%-20%). Additional analyses determined the incremental cost of vaccinating an individual and the cost per averted congestive heart failure case. Vaccination was considered highly cost-effective when the ICER was ≤1 times the GDP/capita, still cost-effective when the ICER was between 1 and 3 times the GDP/capita, and not cost-effective when the ICER was.>3 times the GDP/capita. Our results showed vaccination to be very cost-effective and often economically dominant (i.e., saving costs as well providing health benefits) for a wide range of scenarios, e.g., even when risk of infection was as low as 1% and vaccine efficacy was as low as 25%. Vaccinating an individual could likely provide net cost savings that rise substantially as risk of infection or vaccine efficacy increase. Conclusions/Significance:Results indicate that a T. cruzi vaccine could provide substantial economic benefit, depending on the cost of the vaccine, and support continued efforts to develop a human vaccine. © 2010 Lee et al.
Share
Citation/Export: |
|
Social Networking: |
|
Details
Item Type: |
Article
|
Status: |
Published |
Creators/Authors: |
Creators | Email | Pitt Username | ORCID  |
---|
Lee, BY | byl1@pitt.edu | BYL1 | | Bacon, KM | | | | Connor, DL | | | | Willig, AM | | | | Bailey, RR | | | |
|
Contributors: |
Contribution | Contributors Name | Email | Pitt Username | ORCID  |
---|
Editor | Galvani, Alison P | UNSPECIFIED | UNSPECIFIED | UNSPECIFIED |
|
Date: |
1 December 2010 |
Date Type: |
Publication |
Journal or Publication Title: |
PLoS Neglected Tropical Diseases |
Volume: |
4 |
Number: |
12 |
Page Range: |
1 - 8 |
DOI or Unique Handle: |
10.1371/journal.pntd.0000916 |
Schools and Programs: |
School of Public Health > Epidemiology School of Medicine > Biomedical Informatics |
Refereed: |
Yes |
MeSH Headings: |
Adolescent; Adult; Aged; Aged, 80 and over; Chagas Disease--economics; Chagas Disease--epidemiology; Chagas Disease--prevention & control; Child; Child, Preschool; Cost-Benefit Analysis; Female; Humans; Infant; Infant, Newborn; Latin America--epidemiology; Middle Aged; Models, Statistical; Protozoan Vaccines--economics; Protozoan Vaccines--immunology; Trypanosoma cruzi--immunology; Young Adult |
Other ID: |
NLM PMC3001903 |
PubMed Central ID: |
PMC3001903 |
PubMed ID: |
21179503 |
Date Deposited: |
25 Aug 2012 16:42 |
Last Modified: |
02 Feb 2019 14:55 |
URI: |
http://d-scholarship.pitt.edu/id/eprint/13666 |
Metrics
Monthly Views for the past 3 years
Plum Analytics
Altmetric.com
Actions (login required)
 |
View Item |